Article
Dabrafenib; preclinical characterization, increased efficacy when combined with trametinib, while BRAF/MEK tool combination reduced skin lesions.
PloS one - 1 Jan 2013
King Alastair J, Arnone Marc R, Bleam Maureen R, Moss Katherine G, Yang Jingsong, Fedorowicz Kelly E, Smitheman Kimberly N, Erhardt Joseph A, Hughes-Earle Angela, Kane-Carson Laurie S, Sinnamon Robert H, Qi Hongwei, Rheault Tara R, Uehling David E, Laquerre Sylvie G
Abstract excerpt
Mitogen-Activated Protein Kinase (MAPK) pathway activation has been implicated in many types of human cancer. BRAF mutations that constitutively activate MAPK signalling and bypass the need for upstream stimuli occur with high prevalence in melanoma, colorectal carcinoma, ovarian cancer, papillary thyroid carcinoma, and cholangiocarcinoma. In this report we characterize the novel, potent, and selective BRAF...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.